Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are:
1. To test if 36 weeks of standard dose of ribavirin with PEGASYS® is non-inferior to
standard dose of 48 weeks of ribavirin with PEGASYS® in SVR for patients with RVR and
HVL
2. To test if the 72 weeks of treatment with PEGASYS® plus standard dose ribavirin is
superior to 48 weeks of the same treatment for patients with HCV RNA seropositivity at
week 12
Phase:
Phase 4
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital